During the past decade, Klaipėda University Hospital conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 30 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 18 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klaipėda University Hospital" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Celgene" with 6 trials sponsored, "Bayer" with 5 trials sponsored, "Ipsen" with 4 trials sponsored and "Janssen Research & Development, LLC" with 4 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klaipėda University Hospital" #1 collaborator was "OCT Clinical Trials" with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Barbara Ann Karmanos Cancer Institute" with 1 trials as a collaborator and "BratislavaNemocnica ak. L Derera, Urologicka klinika" with 1 trials as a collaborator. Other collaborators include 50 different institutions and companies that were collaborators in the rest 60 trials.

According to Clinical.Site data, the most researched conditions in "Klaipėda University Hospital" are "Rheumatoid Arthritis" (6 trials), "Prostate Cancer" (4 trials), "Crohn Disease" (3 trials), "Multiple Sclerosis" (3 trials) and "Colitis, Ulcerative" (2 trials). Many other conditions were trialed in "Klaipėda University Hospital" in a lesser frequency.

Most popular intervention types in "Klaipėda University Hospital" are "Drug" (51 trials), "Other" (11 trials), "Biological" (6 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Ozanimod" (4 trials), "Ocrelizumab" (3 trials), "Adalimumab" (2 trials) and "Darolutamide (Nubeqa, BAY1841788)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klaipėda University Hospital" are 47 trials for "All" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Klaipėda University Hospital". undefined are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in Klaipėda University Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Klaipėda University Hospital, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".